Hutchison Medipharma Limited
Clinical trials sponsored by Hutchison Medipharma Limited, explained in plain language.
A biopharmaceutical company developing cancer therapies.
Trade on eToro (ad)Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
-
New pill combo shows promise against resistant lung cancer
Disease control CompletedThis study tested whether combining two targeted drugs, savolitinib and osimertinib, works better than standard chemotherapy for people with advanced non-small cell lung cancer that has a specific genetic change (MET amplification) and has stopped responding to initial treatment.…
Phase: PHASE3 • Sponsor: Hutchison Medipharma Limited • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
New drug combo shows promise for Hard-to-Treat cancers
Disease control CompletedThis study tested a new oral drug called HMPL-453 tartrate, either alone or combined with chemotherapy or an immunotherapy (toripalimab), in 190 people with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety and see if th…
Phase: PHASE1, PHASE2 • Sponsor: Hutchison Medipharma Limited • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
Targeted drug shows promise for hard-to-treat stomach cancers
Disease control CompletedThis study tested a drug called savolitinib in 110 people with advanced stomach or esophagus-stomach junction cancer whose tumors have a specific genetic change (MET gene amplification). The goal was to see if the drug could shrink tumors and how safe it was. Participants receive…
Phase: PHASE2 • Sponsor: Hutchison Medipharma Limited • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
New drug cocktail shows promise for tough stomach cancer
Disease control CompletedThis study tested whether adding fruquintinib to standard chemotherapy (paclitaxel) helps people with advanced stomach cancer live longer. It included 703 patients whose cancer had worsened after initial treatment. The goal was to see if the combination improves survival and slow…
Phase: PHASE3 • Sponsor: Hutchison Medipharma Limited • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC